Apogee Therapeutics, Inc. APGE
We are a clinical stage biotechnology company advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology ("I&I") markets, including for the treatment of atopic dermatitis ("AD"), asthma, eosinophilic esophagitis ("EoE"), chronic obstructive pulmonary disease ("COPD"), and other I&I indications. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties.
Our pipeline comprises multiple antibody programs being developed initially for the treatment of I&I indications as monotherapies and combinations, including zumilokibart (APG777), APG279 (zumilokibart + APG990), APG273 (zumilokibart + APG333), and APG808 (each, a "program" or "product candidate"). With four validated targets in our portfolio, we are seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of our novel antibodies. Based on a broad pipeline and depth of expertise, we believe we can deliver value and meaningful benefit to patients underserved by today's standard of care. We believe each of our product candidates has potential for broad application across multiple I&I indications.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $214.7M | $167.9M | $68.4M | $27.8M |
| SG&A | $70.9M | $49.0M | $24.6M | $2.9M |
| Total operating expenses | $285.6M | $216.9M | $93.0M | $30.7M |
| Operating income | -$285.6M | -$216.9M | -$93.0M | -$30.7M |
| Pre-tax income | -$255.6M | -$182.1M | -$84.0M | — |
| Income tax | $278.0K | $18.0K | $0 | — |
| Net income | -$255.8M | -$182.1M | -$84.0M | -$39.8M |
| EPS, basic | -4.22 | -3.30 | -3.36 | -16.16 |
| EPS, diluted | -4.22 | -3.30 | -3.36 | -16.16 |
| Shares, diluted (wtd. avg.) | 60.7M | 55.2M | 25.0M | 2.5M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $131.5M | $141.8M | $118.3M | $151.9M |
| Short-term investments | $598.6M | $378.9M | $277.1M | — |
| Total current assets | $741.4M | $529.7M | $398.4M | $152.1M |
| Property, plant and equipment | $5.7M | $2.0M | $377.0K | — |
| Total assets | $937.1M | $754.0M | $401.4M | $152.1M |
| Accounts payable | $1.2M | $1.1M | $2.1M | $418.0K |
| Total current liabilities | $27.9M | $28.6M | $20.6M | $10.0M |
| Total liabilities | $33.3M | $37.2M | $21.5M | $10.0M |
| Retained earnings | -$561.8M | -$305.9M | -$123.8M | -$39.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$227.4M | -$171.2M | -$74.8M | -$16.4M |
| Depreciation and amortisation | $1.4M | $189.0K | — | — |
| Stock-based compensation | $46.3M | $23.3M | $6.1M | $2.1M |
| Capital expenditure | $5.1M | $1.2M | $167.0K | — |
| Investing cash flow | -$179.6M | -$300.5M | -$273.9M | — |
| Financing cash flow | $396.5M | $495.1M | $315.4M | $168.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-177342.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Net income | -$39.8M | -$84.0M | -$182.1M | -$255.8M |
Recent filings and events
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Change of control Control of the company has changed hands. Item 5.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |